Barinthus Biotherapeutics (BRNS) News Today

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 29,800 shares, an increase of 223.9% from the June 30th total of 9,200 shares. Based on an average trading volume of 24,300 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the company's shares are sold short.

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 7,200 shares, an increase of 24.1% from the May 31st total of 5,800 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company's stock are sold short.

William Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a research note on Thursday.

Barclays reduced their price objective on Barinthus Biotherapeutics from $7.00 to $3.00 and set an "overweight" rating on the stock in a research note on Thursday.

HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of Barinthus Biotherapeutics in a report on Friday.

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 9,100 shares, a decrease of 52.1% from the April 30th total of 19,000 shares. Based on an average daily trading volume, of 22,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the company's shares are short sold.

HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Thursday.

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Equities research analysts at William Blair raised their Q2 2024 earnings per share (EPS) estimates for Barinthus Biotherapeutics in a report issued on Monday, May 13th. William Blair analyst A. Hsieh now forecasts that the company will

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 22,000 shares, the short-interest ratio is currently 0.6 days.

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 10,100 shares, a decrease of 15.1% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company's stock are short sold.

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - William Blair issued their Q1 2025 EPS estimates for shares of Barinthus Biotherapeutics in a report released on Wednesday, March 20th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.71) for

HC Wainwright decreased their target price on shares of Barinthus Biotherapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday.

Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price Up 3.1%

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Stock analysts at HC Wainwright boosted their FY2023 earnings per share (EPS) estimates for shares of Barinthus Biotherapeutics in a research report issued on Monday, January 8th. HC Wainwright analyst Y. Chen now forecasts that the comp

William Blair reiterated an "outperform" rating on shares of Barinthus Biotherapeutics in a research report on Monday.